DPP4 and hepatocellular carcinoma: In syngeneic mouse models of hepatocellular carcinoma and breast cancer, additional treatment with an antidiabetic drug, the dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin, was shown to promote intratumoral recruitment of eosinophils.